Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230446 | 1.00 | NPC1 (0.44) | NPC1RAB9ALMNAMETAP2METAP1 | |
| SCHEMBL3230333 | 0.84 | HSD11B1 (0.43) | NPC1RAB9ASMN1; SMN2SCDKDM4E | |
| SCHEMBL3230328 | 0.84 | HSD11B1 (0.43) | NPC1RAB9ASMN1; SMN2SCDKDM4E | |
| SCHEMBL3225971 | 0.84 | SCD (0.49) | SCDAOC3HSD11B1 | |
| SCHEMBL3225964 | 0.84 | SCD (0.49) | SCDAOC3HSD11B1 | |
| SCHEMBL3231161 | 0.84 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2SCDHSD11B1 | |
| SCHEMBL3231167 | 0.84 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2SCDHSD11B1 | |
| SCHEMBL3231947 | 0.83 | SCD (0.43) | SCDAOC3HSD11B1 | |
| SCHEMBL3231954 | 0.83 | SCD (0.43) | SCDAOC3HSD11B1 | |
| SCHEMBL3223344 | 0.83 | SCD (0.41) | SCDAOC3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | NPC1 217/4885RAB9A 2792/4885LMNA 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.